re: Ann: Regulatory Notice on PapType at end ... The TGA listing is a good achievement, although not unexpected.
The next test is will any one use it. The Australian market is probably not big enough and the EU already has lots of HPV genotyping assays and service companies. The GBI assay also relies on an expensive instrument platform to work, which puts it at a distinct disadvantage compared to other tests.
